Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Ostrava – page 35

557 clinical trials in Ostrava, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Ostrava at a glance
557
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

557 trials in Ostrava

Open in trial search

Fallopian tube cancer+2

Not recruiting

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Cardiac failure acute

Not recruiting

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:The Brigham And Women’s Hospital Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:LEO PHARMA A/S

Primary progressive multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia (in remission)

Not recruiting

Study of Venetoclax and Azacitidine for Maintenance Therapy in Patients with Acute Myeloid Leukemia in First Remission After Chemotherapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Heart failure with reduced ejection fraction

Not recruiting

Study on JTT-861 for Patients with Heart Failure with Reduced Ejection Fraction

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Akros Pharma Inc.

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Ostrava

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer and lung cancer treatments. Studies include evaluation of novel therapies for multiple myeloma and various forms of leukemia.

  • Prostate Cancer Treatment Advances
  • Small Cell Lung Cancer Therapy
  • Blood Cancer Interventions

Multiple collaborative studies exploring targeted therapies and combination treatments for advanced-stage cancers.

02 Immunology and Inflammatory Diseases

Research targeting inflammatory bowel diseases, including studies on Crohn's Disease and ulcerative colitis. Investigations into novel treatments for psoriatic arthritis.

  • Inflammatory Bowel Disease Management
  • Autoimmune Conditions
  • Chronic Inflammatory Disorders

Comprehensive evaluation of innovative therapeutic approaches for chronic inflammatory conditions.

03 Cardiovascular and Infectious Diseases

Studies examining cardiovascular disease treatments and prevention strategies. Research on bacterial infections and antimicrobial therapies, including trials for complicated urinary tract infections.

  • Heart Disease Prevention
  • Infection Management
  • Antibiotic Optimization

Advanced research combining preventive approaches with targeted therapeutic interventions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.